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Abstract
This review highlights advances in acute pancreatitis (AP) made in the past year. We focus on clinical
aspects of AP - severe disease especially - and risk stratification tools to guide the clinical care of
patients. Most patients with AP have mild disease that requires a diagnostic evaluation, self-limited
supportive care, and a short hospital stay. In patients with potentially severe AP, it is important for
clinicians to use available risk-stratifying tools to identify high-risk patients and initiate timely
interventions such as aggressive fluid resuscitation, close monitoring, early initiation of enteral
nutrition, and appropriate use of endoscopic retrograde cholangio-pancreatography. This approach
decreases morbidity and possibly mortality and is supported by evidence drawn from recent clinical
guidelines, historical literature, and the highest quality studies published in the last year.
Introduction and context
Several major clinical guidelines provide evidence-based
recommendations for clinical management decisions
in acute pancreatitis (AP), including those from the
American College of Gastroenterology (2006) [1], the
American Gastroenterology Association (2007) [2],
the International Association of Pancreatology (2002)
[3], and the International Critical Care Consensus
Conference (2004) [4]. In this update on AP, we briefly
discuss guideline recommendations and focus on
epidemiology, risk factors, etiology, diagnosis, risk
stratification, and recent advances in treatment, includ-
ing chemoprevention of post-endoscopic retrograde
cholangio-pancreatography (ERCP) pancreatitis, early
ERCP treatment for acute biliary pancreatitis (ABP),
intravenous fluid resuscitation, enteral nutrition (EN),
antibiotic prophylaxis, and probiotic therapy.
Recent advances
Epidemiology
Hospital admissions for AP are increasing in the US [5].
Brown and colleagues [5] reported a nationwide increase
of 30.2% (P < 0.001) after identifying 1,476,498
admissions with a primary discharge diagnosis of AP in
the National Inpatient Sample Database for the years
1997 to 2003. This increase was associated with a parallel
increase in gallstone and alcohol-related pancreatitis.
The authors attributed these findings to an increased
incidence of AP and/or to more diligent diagnoses
because of better diagnostic tests (for example, com-
puted tomography [CT], endoscopic ultrasound [EUS],
and ERCP). Over the time span of the study (1997 to
2003), mean mortality decreased from 1.9% to 1.4%
(P < 0.001) and median length of stay decreased from
6.4 to 5.8 days (P = 0.002), which the authors ascribe to
more routine use of risk stratification tools, increased
availability and efficiency of diagnostic tools, and
expedited triage of moderate-severe cases to aggressive
management in intensive care units (ICUs) [5].
New mortality data in AP confirm that mortality rates are
similar in gallstone and alcohol-induced AP [6], that
mortality is 20% in those hospitalized more than 1
month with severe AP (SAP) [7], and that increased
mortality occurred in those with hospital-acquired
infection [8] and those at least 70 years old [9]. Finally,
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pancreatic necrosis are associated with recurrent AP [10].
Risk factors
Cigarette smoking is an independent risk factor for AP
(95% confidence interval = 1.48 to 3.09) and total
exposure correlates with overall risk [11]. Recurrent
attacks of alcoholic AP, however, were not associated
with cigarette smoking [12] but occurred less frequently
in those who had repeated 6-month counselling sessions
(to encourage sobriety) compared with a single session
(8% versus 21%, P = 0.042) [13]. These data reinforce the
common sense approach of encouraging drinking
cessation.
Whether age and gender affect the risk of post-ERCP
pancreatitis (PEP) is controversial [14,15]. According to a
multicenter Chinese trial, however, PEP was associated
with female gender (P = 0.002), age of not more than
60 years (P = 0.025), and other procedural factors [16]. In
a smaller study, obesity was not a risk factor for PEP [17],
however, an increased risk of PEP was associated with
current alcohol use and former smoking (P < 0.0001,
P =0 . 0 1 3 )[ 1 8 ] .
Chemoprevention of post-ERCP pancreatitis
Several groups (re)examined chemoprevention therapy
for PEP by randomized controlled trials (RCTs) [19-23]
and meta-analyses [24-29] and reported inconclusive
results for allopurinol [19,24,25], corticosteroids [26],
unfractionated heparin [20], and intravenous nitrogly-
cerin [21,27,28]. One exception is that prophylactic
rectal nonsteroidal anti-inflammatory drugs (indo-
methacin or diclofenac) may reduce PEP, based on
data from RCTs [22,30] and a meta-analysis of four RCTs
[29]. For unclear reasons, the route of drug delivery may
have critical importance; oral diclofenac did not reduce
PEP [23]. A large, multicenter, prospective RCT is
warranted to determine whether rectally delivered
diclofenac reduces PEP in high-risk patients.
Etiology and diagnosis
ERCP is an effective diagnostic and therapeutic test to
evaluate patients with suspected biliary obstructive
diseases. Unfortunately, ERCP has risks of pancreatitis,
cholangitis, perforation, and hemorrhage. To compare
clinical approaches, Lee and colleagues [31] randomly
assigned 65 patients with suspected biliary obstruction
to an initial ERCP versus EUS. Biliary lesions were
detected in seven out of 33 (22%) ERCP patients and
nine out of 32 (27%) EUS patients and were treated
endoscopically. Serious complications were not signifi-
cantly higher in the ERCP versus EUS group. Because
75% of patients had no biliary lesion, the authors
concluded that most patients can avoid an unnecessary
ERCP if EUS is used as a tool to select appropriate
patients for ERCP.
Investigators previously established that patients with
severe chronic renal insufficiency have pancreatic lesions
[32] and a predilection to pancreatic diseases [33]. Also,
Owyang and colleagues [34,35] reported that patients
with renal failure undergoing hemodialysis (HD) have
increased circulatory gastrointestinal hormones, particu-
larly cholecystokinin (CCK) [34] and increased secretion
of trypsin [35], which the authors postulated could
initiate pancreatic disease in this group of patients [35].
To investigate the incidence and severity of AP associated
with chronic dialysis, Lankisch and colleagues [36]
surveyed dialysis center physicians in Germany.
Seventy-two percent of physicians responded. After
excluding patients with a known cause of AP, the authors
found that dialysis, particularly peritoneal dialysis (PD),
was a risk factor for developing AP. The rates of incidence
of AP (per 100,000) in patient groups were 168 for PD,
32 for HD, and 19.7 for the general population. Finally,
the severity of AP was generally greater in PD than HD
patients. We caution that renal disease rather than
treatment (dialysis) may increase the risk of AP because
renal disease without dialysis was not included as a
control population and because other investigators
reported a higher risk of AP in patients undergoing PD
versus HD (18.4 versus 16.5 per 1,000 person-years;
P = 0.033) [37]. Differences between these studies may
be attributable to biases from the retrospective design,
incomplete data collection, over- or under-reporting of
AP, or other biases.
Risk stratification
Investigators recently [38] reconfirmed an older observa-
tion [39] and conclusions from a practice guideline [1]
that persistent early organ failure (>48 hours) and
pancreatic necrosis (which may not be detectable for
72 hours) are the two most important indicators of
severity in AP [1]. Within the first 48 hours of
presentation, however, these parameters rarely aid risk
stratification, which is important for prognosis, triage,
and directed treatment aimed at decreasing morbidity
and possibly mortality. Other methods of risk stratifica-
tion in AP suffer from the same limitation (Ranson and
Glasgow scores require 48 hours to complete) or require
many factors, including those not directly relevant to AP
prognosis [Acute Physiology and Chronic Health Evalua-
tion II (APACHE II)]. Recent investigators studied
whether computer-based and/or simple scoring systems
quickly and accurately predicted severity and mortality of
AP at presentation.
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of severity by using machine learning, including artificial
neural networks [40,41]. Pearce and colleagues [42]
reported in a retrospective study that kernel logistic
regression and bootstrapping employing eight variables
had 87% sensitivity and 71% specificity for predicting
SAP, values superior to APACHE II. Wu and colleagues
[43] developed a simple, five-component, prognostic
clinical score by performing a classification and regres-
sion tree (CART) analysis on data collected from 17,992
cases of AP hospitalized during the period of 2000 to
2001. The authors identified five variables during the
first 24 hours which predict in-hospital mortality based
on a BISAP (contraction for the five variables) score of
0t o5 :blood urea nitrogen (BUN) of greater than 25 mg/
days, impaired mental status, systemic inflammatory
response syndrome (SIRS), age of more than 60 years, or
the presence of a pleural effusion. Mortality ranged from
less than 1% (0 to 1 point) to as high as 26.7%
(5 points). As a third risk stratification tool, the early
warning score (EWS), a simple physiological scoring
system that monitors patient progress, predicts mortality
of AP based on five bedside parameters: blood pressure,
urine output, respiratory rate, pulse rate, and level of
consciousness. In a retrospective analysis of 181 patients
hospitalized with AP, EWS was as accurate as APACHE II
but easier to use for predicting mortality up to 3 days
after initial presentation [44].
The 1992 Atlanta classification of AP remains the
only classification system used widely by clinicians
because it was an attempt to achieve uniform criteria to
determine clinical severity and complications of AP.
Unfortunately, as Bollen and colleagues [45] reported
after reviewing 447 articles, many of the original
definitions have shortcomings and standardized defini-
tions frequently are not usedtopredictSAP.Clinical trials,
therefore, are heterogeneous; thus, it is difficult if not
impossible to compare studies or pool data to generate
evidence-based recommendations. Subsequently, the
authors suggested that an update or a new classification
of AP was needed.
Fluid resuscitation
Recently published guidelines strongly urge adequate
early fluid resuscitation to correct intravascular volume
depletion (Table 1) [1,2,46-49], a leading contributor to
necrotizing pancreatitis. Gardner and colleagues [9],
however, pointed out that often there are only experi-
mental animal data or uncontrolled human data but no
prospective human studies to use as a basis for making
recommendations. Unanswered questions include the
best measure of intravascular volume status, the optimal
fluid type (crystalloid versus colloid), optimal volume
of fluid resuscitation, optimal timing of fluid adminis-
tration in the course of AP, and the frequency and type of
complications due to fluid resuscitation.
In the absence of reliable data, the authors [9]
recommended that the adequacy of fluid resuscitation
be determined by frequent vitals, urinary output, and
measures of hemoconcentration [9]. A pitfall of aggres-
sive volume resuscitation is the risk of inducing
pulmonary edema/fluid overload. Underlying morbid
conditions or clinical indicators of predicted SAP may
precipitate admission to an ICU for hemodynamic
assessment. To assess preload, intrathoracic blood
volume index (ITBI) might be superior to measurement
of central venous pressure (CVP). It is important to point
out that the use of ITBI requires ICU care because
invasive monitoring with arterial line and pulmonary
artery catheter to perform transpulmonary thermodilu-
tion is required. According to a recent study [50], ITBI
and changes in ITBI correlated significantly with cardiac
index (CI) and changes in CI, respectively, but CVP did
not. An additional advantage of ITBI is that mechanical
ventilation impairs measurement of CVP and pulmonary
capillary wedge pressure (PCWP), but not ITBI. Further-
more, when ITBI was used as the gold standard, CVP and
hematocrit had unacceptably low sensitivities for
Table 1. Fluid resuscitation recommendations from recent reviews of acute pancreatitis
Investigators Journal, year Initial resuscitation recommendation
a
Pandol, et al. [46] Gastroenterology, 2007 Severe volume depletion: 500-1,000 cc/hour
Nonpancreatic fluid loss: 300-500 cc/hour
No volume depletion: 250-350 cc/hour
Forsmark and Baillie [2] Gastroenterology, 2007 Vigorous fluid resuscitation
Urine output ≥0.5 mL/kg body weight/hour
Whitcomb [47] N Engl J Med, 2006 Fluid bolus to achieve hemodynamic stability
followed by 250-500 mL/hour of crystalloid
Banks and Freeman [1] Am J Gastroenterol, 2006 Aggressive intravenous fluid replacement
Swaroop, et al. [48] JAMA, 2004 Aggressive fluid resuscitation
Tenner [49] Am J Gastroenterol, 2004 At least 250-300 cc/hour for 48 hours
aAssuming normal-sized individual without cardiac, pulmonary, or renal compromise. Adapted with permission from Elsevier [9].
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ITBI is more appropriate than CVP or hematocrit for
volume management.
ERCP treatment for pancreatitis
There is consensus [1-4] that (a) ERCP and endoscopic
sphincterotomy are indicated within 24 hours in patients
with ABP with obstructive jaundice and/or acute
cholangitis and (b) routine ERCP prior to cholecystect-
omy is not required in most patients with ABP and mild
disease because bile duct stones typically pass sponta-
neously. Consensus is lacking, however, as to whether
ERCP and endoscopic sphincterotomy should be per-
formed within 72 hours to manage patients with severe
ABP without jaundice or cholangitis. Guidelines cau-
tiously endorse early ERCP in this population, particu-
larly in those with evidence of organ failure. Yet two
recent meta-analyses provide little enthusiasm for this
approach. In two separate meta-analyses [51,52], inves-
tigators reported that early ERCP had no significant
impact on mortality [51,52], including a subgroup of
patients with predicted SAP [51,52] and that early ERCP
had no effect on complications [51] or reduced
complications in patients with predicted SAP [52]. The
modestly different conclusions reached by these two
meta-analyses may be due to many factors, including
different inclusion data and methodological quality and
the use of different definitions for ‘early’ ERCP, predicted
severity of ABP, complications, and cholangitis.
Nutrition
Recent clinical guidelines [1,4,53] and a technical review
[2] recommend administering EN rather than parenteral
nutrition (PN) or no nutrition to (a) patients with
predicted SAP or (b) those who will not be able to
consume food for several weeks. EN is a less costly
nutritional choice than PN and appears to reduce
infectious complications, possibly by maintaining gut
integrity (as a source of bacterial infection) and/or
augmenting glycemic control [54]. This endpoint is
clinically important because infectious complications are
responsible for up to 50% of mortality in patients with
SAP [39,48,55]; when mortality from infection occurs, it
usually does so more than 14 days into the disease
course. Two recent meta-analyses [56,57] show that EN
versus PN reduces the risk of infectious complications
and mortality in patients with predicted SAP. Only the
larger meta-analysis (six versus five RCTs) [57] showed
that EN versus PN reduced organ failure, likely because
of greater power. Similar to these observations, three
recent systematic reviews reported that EN versus PN
reduces the risk of infectious complications in patients
with predicted SAP [58-60]. Interestingly, one systematic
review [61] also reported that only early EN (started at
less than 24 or 48 hours) reduced multiple organ failure
and pancreatic infectious complications and that delayed
EN (>48 hours) or PN had no effect on these endpoints.
Despite the promise of using EN to reduce morbidity,
organ failure, and mortality in predicted SAP, it is
important to identify specific limitations of RCTs
included in these meta-analyses: small size, inconsistent
masking of investigators/patients, and variable defini-
tions for organ failure and criteria for predicting disease
severity. Across studies, there were also differences in the
type of enteral tube (nasogastric versus nasojejunal), the
starting time of EN after admission (range from less than
6 to more than 96 hours), the feeding formula, and the
use of prophylactic antibiotics (73-100%). Further study
is required to determine the appropriate timing of
starting EN, the optimal rate and composition [62,63]
of EN, and whether nasogastric EN has safety and
effectiveness similar to those of nasojejunal EN [64].
Currently, the National Institutes of Health is funding a
multicenter trial to compare the outcomes of nasogastric
versus mid-jejunal feeding in patients with SAP.
Antibiotics
Recent clinical guidelines [1,4], a technical review [2],
and expert opinion [65,66] do not recommend prophy-
lactic systemic antibiotics in patients with acute necrotiz-
ing pancreatitis (ANP). This recommendation arises
from the data of two large (n = 100 to 114 patients),
multicenter (n = 19 to 32 centers), double-blind RCTs
[67,68]; prophylactic antibiotic treatment with Merope-
nem [67] or ciprofloxacin plus flagyl [68] had no
beneficial effect on patients with confirmed ANP [67]
or predicted SAP [68]. Similarly, investigators of a recent
but smaller (n = 46) double-blind RCT reported that
prophylactic administration of intravenous ciprofloxacin
did not reduce pancreatic infections or mortality in
patients with confirmed ANP (n = 46 patients) [69].
Perhaps starting antibiotic prophylaxis earlier than 72 to
120 hours after the onset of symptoms [67,68] rather
than waiting for pancreatic necrosis to appear on CT
imaging (usually occurs 72 hours after the onset of
symptoms) might allow better penetration of antibiotics
into pancreatic tissue and reduce infection [70,71].
Answering this question requires starting antibiotics
within 24 hours of symptom onset on the basis of the
presence of SIRS or predicted SAP [67,69].
The results of five meta-analyses [72-76] performed since
2006 add little new information but are varied and
contrast with findings of the two large, multicenter RCTs.
Three meta-analyses show that prophylactic antibiotics
for ANP and/or SAP reduce hospital stay [74-76], one
shows a reduction in infected necrosis and nonpancreatic
infections [75], and none shows an effect on the rate of
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analyses performed in one meta-analysis raised the
possibly that the use of carbapenems is critical to
outcomes [75], the largest and highest quality RCT
using Meropenem was negative [67], and the meta-
analysis with a stricter requirement for methodological
quality was negative [72].
Hence, based on evidence from well-designed, double-
blind RCTs, we do not recommend the use of prophy-
lactic antibiotics for ANP. According to expert opinion
[65,66,68], prophylactic antibiotics may be considered
to treat patients who have evidence of SIRS or failure of
one or more organs, but this remains controversial and
requires further study. Finally, we recommend antibio-
tics when patients have evidence of sepsis or proven
pancreatic or extrapancreatic infection.
Probiotics
Besselink and colleagues [77] hypothesized that, similar
to the use of EN, probiotic treatment might reduce
infectious complications in SAP by ‘reducing small-
bowel bacterial overgrowth, restoring gastrointestinal
barrier function, and modulating the immune system’.
Two small (n = 45 to 60 patients), double-blind RCTs
performed by the same group of investigators reported
conflicting effects of probiotics on infected necrosis in
patients with AP [78,79]. The much larger (n = 298
patients) double-blind RCT by Besselink and colleagues
[77] included only those with predicted SAP and
administered a multispecies probiotic preparation or
placebo (with the EN) starting within 72 hours of the
onset of symptoms and continuing twice daily for
28 days. Surprisingly, probiotic prophylaxis did not
reduce the risk of infectious complications and was
associated with a higher incidence of bowel ischemia
(9/153 versus 0/145, P = 0.004) and greater mortality
(relative risk = 2.53, 95% confidence interval = 1.22 to
5.25), leading to the logical recommendation that
probiotic prophylaxis not be administered in this
category of patients until the mechanisms of these
adverse events have been clarified [77].
Implications for clinical practice
The primary determinants of mortality in patients with
AP are organ failure during the early phase (from onset to
14 days) and infected necrosis in the late phase (>2
weeks of illness). To reduce morbidity and possibly
mortality, we recommend an expedient workup and risk
stratification of these patients at the point of contact,
usually the emergency department. Fortunately, new
user-friendly risk stratification tools (for example,
BISAP) may simplify and expedite the triage of these
patients to an appropriate level of care, which differs
markedly for high- and low-risk groups. Immediate
treatment decisions for the high-risk group (patients with
organ failure or predicted SAP) include aggressive
resuscitation (for example, 250-500 mg/hour), hemody-
namic monitoring (for example, ITBI), hourly clinical
reassessment in an ICU or stepdown unit, and involve-
ment of a multidisciplinary team. Urgent decisions
include ERCP for some cases of biliary pancreatitis,
initiation of EN after fluid resuscitation (24-48 hours)
and reservation of antibiotics for evidence of sepsis or
SIRS, failure of one or more organs, proven pancreatic or
extrapancreatic infection, or an increase in C-reactive
protein with evidence of pancreatic or extrapancreatic
infection. Late decision making involves continued
reassessment, monitoring for complications, aspiration
and possibly drainage when infected necrosis is sus-
pected, and timely cholecystectomy when warranted.
Table 2 summarizes major advances in acute pancreatitis
(AP) made in the past year that may affect clinical
practice.
Abbreviations
ABP, acute biliary pancreatitis; ANP, acute necrotizing
pancreatitis; AP, acute pancreatitis; APACHE II, Acute
Physiology and Chronic Health Evaluation II; BISAP,
blood urea nitrogen, impaired mental status, systemic
Table 2. Review highlights
 Hospital admissions for acute pancreatitis (AP) are increasing in the US, yet mortality and length of stay are decreasing.
 Cigarette smoking is an independent risk factor for AP, and total exposure correlates with overall risk.
 Renal disease is associated with AP, but it remains unclear whether the mode of dialysis increases this risk further.
 The user-friendly BISAP (blood urea nitrogen, impaired mental status, systemic inflammatory response syndrome, age, and pleural effusion) score can be
calculated rapidly from five variables during the first 24 hours and predicts in-hospital mortality.
 Intrathoracic blood volume index is superior to central venous pressure and hematocrit for assessing volume depletion and guiding fluid resuscitation
in AP.
 Consensus is lacking on whether endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy should be performed within
72 hours to manage patients with severe biliary AP without jaundice or cholangitis.
 Enteral nutrition reduces the risk of infectious complications and mortality in patients with severe AP.
 Prophylactic systemic antibiotics are not recommended for patients with necrotizing AP.
 It remains controversial whether prophylactic antibiotics are indicated for systemic inflammatory response syndrome or failure of one or more organs
in patients with AP.
 Probiotics are associated with a higher incidence of bowel ischemia and greater mortality in patients with severe AP and should not be used.
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effusion; BUN, blood urea nitrogen; CART, classification
and regression tree; CCK, cholecystokinin; CI, cardiac
index; CT, computed tomography; CVP, central venous
pressure; EN, enteral nutrition; ERCP, endoscopic retro-
grade cholangio-pancreatography; EUS, endoscopic
ultrasound; EWS, early warning score; HD, hemodialysis;
ICU, intensive care unit; ITBI, intrathoracic blood
volume index; PCWP, pulmonary capillary wedge
pressure; PD, peritoneal dialysis; PEP, post-ERCP (endo-
scopic retrograde cholangio-pancreatography) pancrea-
titis; PN, parenteral nutrition; RCT, randomized
controlled trial; SAP, severe acute pancreatitis; SIRS,
systemic inflammatory response syndrome.
Competing interests
MJD received honoraria from Lippincott Williams &
Wilkins (Philadelphia, PA, USA) (for articles published
in Current Opinion in Gastroenterology from 2003 to
2007), honoraria from the British Medical Journal (for an
article published in BMJ Point of Care in 2007), and a
consulting fee from MD Evidence (Atlantic City, NJ,
USA) (for co-authoring a systematic review [80]). E-JW
and ATD declare that they have no competing interests.
This research was supported by an educational grant
from Altus Pharmaceuticals (Waltham, MA, USA).
Acknowledgments
MJD receives research support from National Institute of
Health grants K08 DK073298 and R21 AA017271.
References
1. Banks PA, Freeman ML: Practice guidelines in acute pancreati-
tis. Am J Gastroenterol 2006, 101:2379-400.
2. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics
Committee; AGA Institute Governing Board: AGA Institute
technical review on acute pancreatitis. Gastroenterology 2007,
132:2022-44.
3. Uhl W, Warshaw A, Imrie C, Bassi C, McKay CJ, Lankisch PG,
Carter R, Di Magno E, Banks PA, Whitcomb DC, Dervenis C,
Ulrich CD, Satake K, Ghaneh P, Hartwig W, Werner J, McEntee G,
Neoptolemos JP, Büchler MW; International Association of Pancrea-
tology: IAP Guidelines for the Surgical Management of Acute
Pancreatitis. Pancreatology 2002, 2:565-73.
4. Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand JA,
Skerrett SJ, Stapleton RD, Ware LB, Waldmann CS: Management of
the critically ill patient with severe acute pancreatitis. Crit Care
Med 2004, 32:2524-36.
5. Brown A, Young B, Morton J, Behrns K, Shaheen N: Are health
related outcomes in acute pancreatitis improving? An
analysis of national trends in the U.S. from 1997 to 2003.
JOP 2008, 9:408-14.
6. Andersen AM, Novovic S, Ersboll AK, Hansen MB: Mortality in
alcohol and biliary acute pancreatitis. Pancreas 2008, 36:432-4.
7. Gigout J, Desjeux A, Vitton V, Gasmi M, Subtil C, Grimaud JC,
Barthet M: What is the outcome for patients presenting with
severe acute pancreatitis requiring a hospital stay of more
than one month? Gastroenterol Clin Biol 2009, 33:210-6.
8. Wu BU, Johannes RS, Kurtz S, Banks PA: The impact of hospital-
acquired infection on outcome in acute pancreatitis. Gastro-
enterology 2008, 135:816-20.
F1000 Factor 9.0 Exceptional
Evaluated by Matthew DiMagno 30 Oct 2008
9. Gardner TB, Vege SS, Pearson RK, Chari ST: Fluid resuscitation in
acute pancreatitis. Clin Gastroenterol Hepatol 2008, 6:1070-6.
10. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T,
Kuroda Y: Long-term outcome of severe acute pancreatitis.
J Hepatobiliary Pancreat Surg 2008, 15:397-402.
11. Lindkvist B, Appelros S, Manjer J, Berglund G, Borgstrom A: A
prospective cohort study of smoking in acute pancreatitis.
Pancreatology 2008, 8:63-70.
12. Pelli H, Lappalainen-Lehto R, Piironen A, Sand J, Nordback I: Risk
factors for recurrent acute alcohol-associated pancreatitis: a
prospective analysis. Scand J Gastroenterol 2008, 43:614-21.
13. Nordback I, Pelli H, Lappalainen-Lehto R, Jarvinen S, Raty S, Sand J:
The recurrence of acute alcohol-associated pancreatitis can
be reduced: a randomized controlled trial. Gastroenterology
2008, 136:848-55.
F1000 Factor 6.0 Must Read
Evaluated by Dhiraj Yadav 27 Feb 2009
14. Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J,
Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS,
Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pannell L,
Rashdan A, Temkit M, Lehman GA: Risk factors for post-ERCP
pancreatitis: a prospective multicenter study. Am J Gastroenterol
2006, 101:139-47.
15. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG,
Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ,
Snady HW, Erickson RV, Moore JP, Roel JP: Risk factors for post-
ERCP pancreatitis: a prospective, multicenter study. Gastro-
intest Endosc 2001, 54:425-34.
16. Wang P, Li ZS, Liu F, Ren X, Lu NH, Fan ZN, Huang Q, Zhang X,
He LP, Sun WS, Zhao Q, Shi RH, Tian ZB, Li YQ, Li W, Zhi FC: Risk
factors for ERCP-related complications: a prospective multi-
center study. Am J Gastroenterol 2009, 104:31-40.
17. Deenadayalu VP, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J,
Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS,
Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Temkit M, Lehman GA,
Sherman S: Does obesity confer an increased risk and/or more
severe course of post-ERCP pancreatitis? a retrospective,
multicenter study. J Clin Gastroenterol 2008, 42:1103-9.
18. DeBenedet AT, Raghunathan TE, Wing JJ, Wamsteker EJ, DiMagno MJ:
Current alcohol use and former cigarette smoking as risk
factors for post-endoscopic retrograde cholangiopancreato-
graphy pancreatitis. Clin Gastroenterol Hepatol 2009, 7:353-8.
19. Romagnuolo J, Hilsden R, Sandha GS, Cole M, Bass S, May G, Love J,
Bain VG, McKaigney J, Fedorak RN: Allopurinol to prevent
pancreatitis after endoscopic retrograde cholangiopancrea-
tography: a randomized placebo-controlled trial. Clin Gastro-
enterol Hepatol 2008, 6:465-71.
F1000 Factor 6.0 Must Read
Evaluated by Matthew DiMagno 2 Jun 2008
20. Barkay O, Niv E, Santo E, Bruck R, Hallak A, Konikoff FM: Low-dose
heparin for the prevention of post-ERCP pancreatitis: a
randomized placebo-controlled trial. Surg Endosc 2008,
22:1971-6.
21. Beauchant M, Ingrand P, Favriel JM, Dupuychaffray JP, Capony P,
Moindrot H, Barthet M, Escourrou J, Plane C, Barrioz T, Lacoste L,
Ingrand I: Intravenous nitroglycerin for prevention of pancrea-
titis after therapeutic endoscopic retrograde cholangiogra-
phy: a randomized, double-blind, placebo-controlled
multicenter trial. Endoscopy 2008, 40:631-6.
22. Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H,
Zali MR: Role of diclofenac in reducing post-endoscopic
Page 6 of 8
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:59 http://F1000.com/Reports/Medicine/content/1/59retrograde cholangiopancreatography pancreatitis. J Gastro-
enterol Hepatol 2008, 23:e11-6.
23. Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S,
Schmidt S, Lazzell-Pannell L, Lehman GA: Efficacy of diclofenac in
the prevention of post-ERCP pancreatitis in predominantly
high-risk patients: a randomized double-blind prospective
trial. Gastrointest Endosc 2007, 66:1126-32.
24. Bai Y, Gao J, Zhang W, Zou D, Li Z: Meta-analysis: allopurinol in
the prevention of postendoscopic retrograde cholangiopan-
creatography pancreatitis. Aliment Pharmacol Ther 2008,
28:557-64.
25. Zheng M, Chen Y, Bai J, Xin Y, Pan X, Zhao L: Meta-analysis of
prophylactic allopurinol use in post-endoscopic retrograde
cholangiopancreatography pancreatitis. Pancreas 2008,
37:247-53.
26. Zheng M, Bai J, Yuan B, Lin F, You J, Lu M, Gong Y, Chen Y: Meta-
analysis of prophylactic corticosteroid use in post-ERCP
pancreatitis. BMC Gastroenterol 2008, 8:6.
27. Shao LM, Chen QY, Chen MY, Cai JT: Nitroglycerin in the
prevention of Post-ERCP pancreatitis: a meta-analysis. Dig Dis
Sci 2009, [Epub ahead of print].
28. Bang UC, Nøjgaard C, Andersen PK, Matzen P: Meta-analysis:
nitroglycerin for prevention of post-ERCP pancreatitis.
Aliment Pharmacol Ther 2009, 29:1078-85.
29. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD: A
meta-analysis of rectal NSAIDs in the prevention of post-
ERCP pancreatitis. Gut 2008, 57:1262-7.
30. Lankisch PG: Indomethacin may reduce the incidence and
severity of acute pancreatitis after ERCP. Am J Gastroenterol
2008, 103:244.
31. Lee YT, Chan FK, Leung WK, Chan HL, Wu JC, Yung MY, Ng EK,
Lau JY, Sung JJ: Comparison of EUS and ERCP in the
investigation with suspected biliary obstruction caused by
choledocholithiasis: a randomized study. Gastrointest Endosc
2008, 67:660-8.
32. Baggenstoss AH: The pancreas in uremia: a histopathologic
study. Am J Pathol 1948, 24:1003-17.
33. Avram MM: High prevalence of pancreatic disease in chronic
renal failure. Nephron 1977, 18:68-71.
34. Owyang C, Miller LJ, DiMagno EP, Brennan LA Jr, Go VL:
Gastrointestinal hormone profile in renal insufficiency. Mayo
Clin Proc 1979, 54:769-73.
35. Owyang C, Miller LJ, DiMagno EP, Mitchell JC 3rd, Go VL:
Pancreatic exocrine function in severe human chronic renal
failure. Gut 1982, 23:357-61.
36. Lankisch PG, Weber-Dany B, Maisonneuve P, Lowenfels AB:
Frequency and severity of acute pancreatitis in chronic
dialysis patients. Nephrol Dial Transplant 2008, 23:1401-5.
37. Quraishi ER, Goel S, Gupta M, Catanzaro A, Zasuwa G, Divine G:
Acute pancreatitis in patients on chronic peritoneal dialysis:
an increased risk? Am J Gastroenterol 2005, 100:2288-93.
38. Lytras D, Manes K, Triantopoulou C, Paraskeva C, Delis S,
Avgerinos C, Dervenis C: Persistent early organ failure: defining
the high-risk group of patients with severe acute pancreatitis?
Pancreas 2008, 36:249-54.
39. Johnson CD, Abu-Hilal M: Persistent organ failure during the
first week as a marker of fatal outcome in acute pancreatitis.
Gut 2004, 53:1340-4.
40. Pofahl WE, Walczak SM, Rhone E, Izenberg SD: Use of an artificial
neural network to predict length of stay in acute pancreatitis.
Am Surg 1998, 64:868-72.
41. Keogan MT, Lo JY, Freed KS, Raptopoulos V, Blake S, Kamel IR,
Weisinger K, Rosen MP, Nelson RC: Outcome analysis of patients
with acute pancreatitis by using an artificial neural network.
Acad Radiol 2002, 9:410-9.
42. Pearce CB, Gunn SR, Ahmed A, Johnson CD: Machine learning can
improve prediction of severity in acute pancreatitis using
admission values of APACHE II score and C-reactive protein.
Pancreatology 2006, 6:123-31.
43. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA: The
early prediction of mortality in acute pancreatitis: a large
population-based study. Gut 2008, 57:1698-703.
F1000 Factor 6.0 Must Read
Evaluated by Chris Forsmark 1 Jul 2008
44. Garcea G, Gouda M, Hebbes C, Ong SL, Neal CP, Dennison AR,
Berry DP: Predictors of severity and survival in acute
pancreatitis: validation of the efficacy of early warning scores.
Pancreas 2008, 37:e54-61.
45. Bollen TL, van Santvoort HC, Besselink MG, van Leeuwen MS,
Horvath KD, Freeny PC, Gooszen HG: The Atlanta Classification
of acute pancreatitis revisited. Br J Surg 2008, 95:6-21.
46. Pandol SJ, Saluja AK, Imrie CW, Banks PA: Acute pancreatitis:
bench to the bedside. Gastroenterology 2007, 132:1127-51.
47. Whitcomb DC: Clinical practice. Acute pancreatitis. N Engl J
Med 2006, 354:2142-50.
48. Swaroop VS, Chari ST, Clain JE: Severe acute pancreatitis. JAMA
2004, 291:2865-8.
49. Tenner S: Initial management of acute pancreatitis: critical
issuesduringthefirst72hours.AmJGastroenterol2004,99:2489-94.
50. Huber W, Umgelter A, Reindl W, Franzen M, Schmidt C, von
Delius S, Geisler F, Eckel F, Fritsch R, Siveke J, Henschel B,
Schmid RM: Volume assessment in patients with necrotizing
pancreatitis: a comparison of intrathoracic blood volume
index, central venous pressure, and hematocrit, and their
correlation to cardiac index and extravascular lung water
index. Crit Care Med 2008, 36:2348-54.
51. Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ, van
Erpecum KJ, Gooszen HG: Early endoscopic retrograde cholan-
giopancreatography versus conservative management in
acute biliary pancreatitis without cholangitis: a meta-analysis
of randomized trials. Ann Surg 2008, 247:250-7.
52. Moretti A, Papi C, Aratari A, Festa V, Tanga M, Koch M, Capurso L: Is
early endoscopic retrograde cholangiopancreatography use-
ful in the management of acute biliary pancreatitis? A meta-
analysis of randomized controlled trials. Dig Liver Dis 2008,
40:379-85.
53. Meier R, Ockenga J, Pertkiewicz M, Pap A, Milinic N, Macfie J, Loser C,
Keim V: ESPEN Guidelines on Enteral Nutrition: Pancreas. Clin
Nutr 2006, 25:275-84.
54. Petrov MS, Zagainov VE: Influence of enteral versus parenteral
nutrition on blood glucose control in acute pancreatitis: a
systematic review. Clin Nutr 2007, 26:514-23.
55. Gloor B, Muller CA, Worni M, Martignoni ME, Uhl W, Buchler MW:
Late mortality in patients with severe acute pancreatitis. Br J
Surg 2001, 88:975-9.
56. Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ,
Windsor JA, Gooszen HG: Enteral nutrition and the risk of
mortality and infectious complications in patients with
severe acute pancreatitis: a meta-analysis of randomized
trials. Arch Surg 2008, 143:1111-7.
F1000 Factor 3.0 Recommended
Evaluated by Jan De Waele 4 Dec 2008
57. Cao Y, Xu Y, Lu T, Gao F, Mo Z: Meta-analysis of enteral
nutrition versus total parenteral nutrition in patients with
severe acute pancreatitis. Ann Nutr Metab 2008, 53:268-75.
58. Marik PE, Zaloga GP: Meta-analysis of parenteral nutrition
versus enteral nutrition in patients with acute pancreatitis.
BMJ 2004, 328:1407.
59. McClave SA, Chang WK, Dhaliwal R, Heyland DK: Nutrition
support in acute pancreatitis: a systematic review of the
literature. JPEN J Parenter Enteral Nutr 2006, 30:143-56.
60. Petrov MS, Pylypchuk RD, Emelyanov NV: Systematic review:
nutritional support in acute pancreatitis. Aliment Pharmacol Ther
2008, 28:704-12.
Page 7 of 8
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:59 http://F1000.com/Reports/Medicine/content/1/5961. Petrov MS, Pylypchuk RD, Uchugina AF: A systematic review on
the timing of artificial nutrition in acute pancreatitis. Br J Nutr
2009, 101:787-93.
62. Petrov MS, Atduev VA, Zagainov VE: Advanced enteral therapy in
acute pancreatitis: is there a room for immunonutrition?
A meta-analysis. Int J Surg 2008, 6:119-24.
63. Wang X, Li W, Li N, Li J: Omega-3 fatty acids-supplemented
parenteral nutrition decreases hyperinflammatory response
and attenuates systemic disease sequelae in severe acute
pancreatitis: a randomized and controlled study. JPEN J
Parenter Enteral Nutr 2008, 32:236-41.
64. Petrov MS, Correia MI, Windsor JA: Nasogastric tube feeding in
predicted severe acute pancreatitis. A systematic review of
the literature to determine safety and tolerance. JOP 2008,
9:440-8.
65. Lankisch PG, Lerch MM: Pharmacological prevention and
treatment of acute pancreatitis: where are we now? Dig Dis
2006, 24:148-59.
66. DiMagno MJ, DiMagno EP: New advances in acute pancreatitis.
Curr Opin Gastroenterol 2007, 23:494-501.
67. Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T,
Imrie CW, Johnson CD, Knaebel HP, Laterre PF, Maravi-Poma E,
Kissler JJ, Sanchez-Garcia M, Utzolino S: Early antibiotic treat-
ment for severe acute necrotizing pancreatitis: a rando-
mized, double-blind, placebo-controlled study. Ann Surg 2007,
245:674-83.
68. Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, Maier L,
Malfertheiner P, Goebell H, Beger HG: Prophylactic antibiotic
treatment in patients with predicted severe acute pancrea-
titis: a placebo-controlled, double-blind trial. Gastroenterology
2004, 126:997-1004.
69. Garcia-Barrasa A, Borobia FG, Pallares R, Jorba R, Poves I, Busquets J,
Fabregat J: A double-blind, placebo-controlled trial of cipro-
floxacin prophylaxis in patients with acute necrotizing
pancreatitis. J Gastrointest Surg 2009, 13:768-74.
70. Cinar E, Ateskan U, Baysan A, Mas MR, Comert B, Yasar M, Ozyurt M,
Yener N, Mas N, Ozkomur E, Altinatmaz K: Is late antibiotic
prophylaxis effective in the prevention of secondary pancrea-
tic infection? Pancreatology 2003, 3:383-8.
71. Manes G, Uomo I, Menchise A, Rabitti PG, Ferrara EC, Uomo G:
Timing of antibiotic prophylaxis in acute pancreatitis: a
controlled randomized study with meropenem. Am J Gastro-
enterol 2006, 101:1348-53.
72. de Vries AC, Besselink MG, Buskens E, Ridwan BU, Schipper M, van
Erpecum KJ, Gooszen HG: Randomized controlled trials of
antibiotic prophylaxis in severe acute pancreatitis:
relationship between methodological quality and outcome.
Pancreatology 2007, 7:531-8.
73. Bai Y, Gao J, Zou DW, Li ZS: Prophylactic antibiotics cannot
reduce infected pancreatic necrosis and mortality in acute
necrotizing pancreatitis: evidence from a meta-analysis
o fr a n d o m i z e dc o n t r o l l e dt r i a l s .Am J Gastroenterol 2008,
103:104-10.
Changes Clinical Practice
F1000 Factor 3.2 Recommended
Evaluated by Chris Forsmark 27 Feb 2008, Manoop Bhutani 27 Feb
2008
74. Hart PA, Bechtold ML, Marshall JB, Choudhary A, Puli SR, Roy PK:
Prophylactic antibiotics in necrotizing pancreatitis: a meta-
analysis. South Med J 2008, 101:1126-31.
75. Xu T, Cai Q: Prophylactic antibiotic treatment in acute
necrotizing pancreatitis: results from a meta-analysis. Scand J
Gastroenterol 2008, 43:1249-58.
76. Mazaki T, Ishii Y, Takayama T: Meta-analysis of prophylactic
antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006,
93:674-84.
77. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van
Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van
Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA,
Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der
Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG;
Dutch Acute Pancreatitis Study Group: Probiotic prophylaxis in
predicted severe acute pancreatitis: a randomised, double-
blind, placebo-controlled trial. Lancet 2008, 371:651-9.
Changes Clinical Practice
F1000 Factor 8.3 Exceptional
Evaluated by Jan De Waele 29 Feb 2008, Ingvar Bjarnason 29 Feb
2008, Bruce Bistrian 3 Mar 2008, Dhiraj Yadav 19 Aug 2008
78. Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S: Randomized
clinical trial of specific lactobacillus and fibre supplement to
early enteral nutrition in patients with acute pancreatitis. Br J
Surg 2002, 89:1103-7.
79. Olah A, Belagyi T, Poto L, Romics L Jr, Bengmark S: Synbiotic
control of inflammation and infection in severe acute
pancreatitis: a prospective, randomized, double blind study.
Hepatogastroenterology 2007, 54:590-4.
80. Waljee AK, DiMagno MJ, Wu BU, Schoenfeld PS, Conwell DL:
Systematic review: pancreatic enzyme treatment of malab-
sorption associated with chronic pancreatitis. Aliment Pharmacol
Ther 2009, 29:235-46.
Page 8 of 8
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:59 http://F1000.com/Reports/Medicine/content/1/59